Regeneron Pharmaceuticals
About Regeneron Pharmaceuticals
Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates in clinical trials for the potential treatment of obesity, rheumatoid arthritis, and cancer. The Company also has preclinical programs in asthma, allergies, and other diseases and disorders.
Regeneron has several investigational product candidates progressing through all stages of human clinical trials, for a diverse set of serious diseases, including obesity, rheumatoid arthritis, and cancer.
AXOKINE® IL-1 --for the potential treatment of obesity
VEGF Trap -- Research has shown that a protein found in the bloodstream (vascular endothelial growth factor, or VEGF), is secreted by many tumors to stimulate new blood vessels to grow and support the tumor. When VEGF binds to a protein its protein receptor, which resides on the surface of blood vessel cells, it stimulates their growth. In preclinical studies, the VEGF Trap literally “traps” the VEGF being made by the tumor, stopping it from stimulating the VEGF receptor, and thus preventing the tumor from promoting blood vessel growth.
IL-4/13 Trap --Evidence from different laboratories suggests that overproduction of two functionally related cytokines, Interleukin-4 (IL-4) and Interleukin-13 (IL-13),can initiate an immune response that can lead to allergy and asthma. The "IL-4/13 Trap" tightly binds both IL-4 and IL-13 and, in preclinical studies, blocks their actions.
IL-1 Trap - - tightly binds IL-1 and potently blocks its effects. In preclinical studies, the IL-1 Trap decreased inflammation and blocked cartilage erosion in the joint.
More About Regeneron